Abstract
Lung cancer represents a successful example of precision medicine application in medical oncology, since the introduction of routine molecular testing and targeted therapies into clinical practice has significantly contributed to decrease non-small cell lung cancer (NSCLC) patients’ mortality worldwide. International guidelines recommend the routine use of next generation sequencing (NGS) as new standard approach to profile advanced lung adenocarcinoma samples, with the aim of identifying targetable driver mutations that allow patients’ access to effective targeted drugs either available in daily practice or in the context of clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
